Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Sasi Shanmugam Senga

DPhil Student

Research interests

The unidirectional developmental model proposed by Sir Conrad Waddington was defied by Sir John B Gurdon and Yamanaka, similarly histone methylation which serves as a key element of eukaryotic epigenome was believed to be irreversible. This epigenetic dogma was refuted by Professor Yang Shi with the discovery of the first histone demethylase which resulted in a paradigm shift in the field of epigenetics. I proposed epigenetic dysregulation as one of the hallmarks of cancer in my paper the Hallmarks of Cancer - the New Testament. At Ludwig, I am working on the hallmark of epigenetic dysregulation. My research focus is on exploiting epigenetic vulnerabilities to develop novel therapeutic options predominantly for brain cancers and also other cancer types.


I am a Neurosurgical Oncologist with Masters in Neuroscience, Masters in Cancer & Therapeutics, and specialist training in cancer research from the Dana Farber Cancer Institute and the Barts Cancer Institute. I am a UK Commonwealth Scholar and an Oxford Clarendon Scholar and Excellence award/Top Honours award recipient from the Harvard Medical School. I have also authored a few books on cancer.

I run a cancer foundation for the underprivileged in two countries in memory of my mother Kalavathi who passed away due to cancer